Shots:
- BI & Re-Vana Therapeutics have entered into a strategic collaboration & license agreement to develop extended-release therapies for eye diseases
- As per the deal, BI will obtain target exclusivity, while Re-Vana will receive over $1B in total potential deal value for the initial 3 targets, incl. upfront, development, regulatory, & commercial milestones, plus royalties on net sales
- Re-Vana will integrate its extended-release platform with BI’s R&D capabilities & eye health pipeline, incl. 4 P-II assets, as BI aims to add up to 3 projects/yr. across modalities & jointly oversee Re-Vana’s feasibility & development efforts while solely handling clinical, regulatory, & global commercial stages
Ref: GlobeNewswire | Image: Re-Vana Therapeutics and Boehringer Ingelheim |Press Release
Related News:- ViVerita Therapeutics Collaborates with Boehringer Ingelheim to Accelerate Discovery of Novel Therapeutic Targets in Oncology
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
